

Leticia De Mattos-Arruda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4785562/publications.pdf>

Version: 2024-02-01

34
papers

2,876
citations

331670

21
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

5586
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	3.7	5
2	Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e11409.	1.5	8
3	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021, 148, 134-145.	2.8	10
4	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	5.2	2
5	PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come. <i>ESMO Open</i> , 2020, 5, e000890.	4.5	8
6	Clinical implications of intratumor heterogeneity: challenges and opportunities. <i>Journal of Molecular Medicine</i> , 2020, 98, 161-177.	3.9	241
7	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. <i>Cell Reports</i> , 2019, 27, 2690-2708.e10.	6.4	95
8	New emerging targets in cancer immunotherapy: the role of neoantigens. <i>ESMO Open</i> , 2019, 4, e000684.	4.5	20
9	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	4.4	200
10	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	1.8	36
11	News from ASCO 2018. <i>Breast Care</i> , 2018, 13, 298-302.	1.4	0
12	Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 464-474.	4.6	101
13	Translating neoadjuvant therapy into survival benefits: one size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 566-579.	27.6	38
14	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	7.0	119
15	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.	4.5	53
16	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.	2.9	37
17	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , 2015, 6, 8839.	12.8	605
18	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	1.8	135

#	ARTICLE	IF	CITATIONS
19	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	10.7	703
20	Escaping Out of the Brain. <i>Cancer Discovery</i> , 2014, 4, 1259-1261.	9.4	12
21	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , 2014, 8, 1588-1602.	4.6	49
22	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014, 8, 150-158.	4.6	37
23	Brain metastasis: New opportunities to tackle therapeutic resistance. <i>Molecular Oncology</i> , 2014, 8, 1120-1131.	4.6	37
24	Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. <i>Advances in Therapy</i> , 2013, 30, 645-658.	2.9	21
25	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 377-389.	27.6	164
26	Pilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection. <i>Oncologist</i> , 2013, 18, 1180-1188.	3.7	22
27	Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2561-2561.	1.6	2
28	Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 631-644.	3.7	31
29	Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?. <i>Breast</i> , 2012, 21, 604-607.	2.2	20
30	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 509-509.	1.6	3
31	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 566-566.	1.6	0
32	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10511-10511.	1.6	0
33	Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 279-289.	2.3	24
34	Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. <i>Future Oncology</i> , 2011, 7, 1385-1397.	2.4	38